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The curative effect of allogeneic stem cell transplantation (SCT) is due to a cytoreductive effect of chemotherapy and total body irradiation, and an additional immunological effect, which is attributed to T lymphocytes from the healthy stem cell donor. 1 Clinical evidence for this graft-versusleukemia (GVL) effect is found in an increased incidence of relapse of the original disease after SCT with a T celldepleted stem cell graft. [2] [3] [4] [5] Moreover, a relapse of chronic myeloid leukemia (CML) after SCT can be successfully treated by the infusion of peripheral blood mononuclear cells (MNC) from the original stem cell donor. [6] [7] [8] [9] [10] donor leukocyte transfusions (DLT) are often accompanied by graft-versus-host disease (GVHD), bone marrow aplasia or infections. Although it has been suggested that reduction of the number of donor T cells infused may decrease the incidence of GVHD, 11 treatment with cytotoxic T lymphocytes (CTL) that show a relative specificity for the leukemic cells may improve separation of anti-leukemic responses from GVHD and thereby reduce the morbidity and mortality of cellular immunotherapy.
CTL lines and clones reactive with leukemic cells, can be generated in vitro from lymphocytes from the healthy HLA-identical stem cell donors of patients with leukemia. [12] [13] [14] These CTL responses may be directed against polymorphic non-HLA determinants, polymorphic peptides expressed on hematopoietic cells, leukemia-specific or leukemia translocation specific peptides, presented in HLA class I or II expressed on the leukemic cells. 15 However, leukemia-reactive CTL lines often lose their specific cytotoxicity, [16] [17] [18] in part due to overgrowth by non-cytotoxic T cells.
A limiting dilution analysis (LDA) can be used to estimate the number of lymphocytes that respond to a defined antigen. Using LDA, the allo-reactive CTL precursor (CTLp) frequency in peripheral blood of HLA-identical healthy stem cell donors can be calculated and used to identify optimal donor-recipient pairs. 19 Since the alloreactive and leukemia-reactive CTLp frequency in a HLAidentical stem cell donor will be very low, false-negative results may be obtained when bulk cultures are used to study anti-leukemic immune responses. Therefore a modification of the LDA was developed to generate leukemiareactive CTL lines and clones between HLA-identical donor-patient pairs. In this paper we discuss the efficiency of the generation of leukemia-reactive CTL responses in a modified LDA, and the predictive value of cytotoxicity at different stages of the cultures.
Materials and methods

Generation of leukemia-reactive CTL lines
After informed consent bone marrow and peripheral blood from three patients with CML in chronic phase and their HLA-identical donors was obtained. Cells were centrifugated over Ficoll-Isopaque (density 1.077 g/cm 3 , 1000 g, 20 min) and MNC were harvested from the interface. The MNC were cryopreserved in RPMI 1640 (Gibco Laboratories, Grand Island, NY, USA), with 20 g/l human albumin (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands) and 10% DMSO. Donor-derived anti-leukemic CTL lines in flasks were generated as described previously. 13 Briefly, donor-derived MNC were stimulated with twice as many irradiated (25 Gy) leukemic cells of the recipient and cultured in medium consisting of RPMI 1640 supplemented with 20% AIM V (Gibco), 3% donor-derived heparin plasma or with 10% heat inactivated pooled prescreened (HIV-, HBsAg-and allo-antibody negative) human serum, 3 mmol/l glutamine (HyClone Laboratories, Sterile Systems, Logan, UT, USA), 10 g/ml ciprofloxacin (Bayer, Mijdrecht, The Netherlands) and 0.5 g/ml amphotericin B (Bristol Meyers Squibb, Woerden, The Netherlands). After 7 days of culture, 300 IU/ml human recombinant interleukin-2 (IL-2; Roussel Uclaf, Paris, France) was added. The CTL lines were restimulated with two to four times as many irradiated leukemic cells once a week. After 2, 3, 4 and 5 weeks of culture the CTL lines were tested in a 51 Cr release assay.
Generation of leukemia-reactive CTL lines in a LDA
Before use, the cells were thawed, washed twice and resuspended in complete medium, consisting of RPMI 1640 supplemented with 10% pooled human serum, 3 mmol/l glutamine, 100 U/ml penicillin, 100 mol/ml streptomycin (HyClone) and 0.5 g/ml amphotericin B. Two-fold serial dilutions of MNC (from 4 x 10 4 down to 625 responder cells per well) from the three HLA-identical family donors of the patients with CML were cultured in complete medium in at least 24 replicates per concentration in 96-well U-bottom tissue culture plates (Costar, Cambridge, MA, USA). All wells were stimulated with a fixed number (2 x 10 4 ) of irradiated (25 Gy) patient-derived leukemic cells, resulting in stimulator/responder ratios ranging from 32:1 to 1:2. The last 24 wells contained stimulator cells only and were used as a background control. The initial volume in the wells was 100 l. After 7 days of culture, 100 l complete medium plus IL-2 was added at a final concentration of 120 or 300 IU/ml. All wells were restimulated with 1-2 x 10 4 irradiated leukemic cells after 1 and 3 weeks of culture.
The growth of the cell lines was scored using an inverted microscope. A well was defined as proliferative if the estimated cell number was at least 10 000 cells/well. Wells were split using a pipetting robot (Biomek, Beckman Instruments, Mijdrecht, The Netherlands) after 2, 3, 4 and 5 weeks of culture; one half was used to test cytotoxicity, whereas the other half was used for expansion.
Proliferative wells with Ͼ20% specific lysis of leukemic cells were expanded in 50 ml tissue culture flasks (Costar, Cambridge, MA, USA) in a responder cell concentration of 0.1-0.2 x 10 6 /ml and restimulated with irradiated leukemic cells in an estimated S/R ratio of 1:1 every other week. The cell lines were phenotyped and cytotoxicity was tested.
Generation of CTL clones
CTL clones were generated from individual wells containing donor-derived leukemia-reactive T cells by plating the effector cells at concentrations of 10, 3 and 1 cells/well in 96 well U-bottom tissue culture plates in complete medium with 0.4 ng/ml phytohemagglutinin (PHA; Difco Laboratories, Detroit, MI, USA) and 300 IU/ml IL-2. Each well was stimulated with 10 3 irradiated (25 Gy) leukemic cells and 10 4 irradiated (50 Gy) allogeneic third party peripheral blood MNC. After 12-14 days proliferative wells were selected using an inverted microscope and distributed over eight wells in a microtiter plate in the presence of 1-5 x 10 3 irradiated leukemic cells from the patient and/or irradiated (50 Gy) patient-derived Epstein-Barr-transformed B cells (EBV-LCL) and 10 4 irradiated third party peripheral blood MNC. Potential clones were phenotyped and cytotoxicity was tested. CTL clones were further expanded in 50 ml flasks in fresh complete medium with IL-2 in the presence of irradiated specific and non-specific stimulator cells.
Analysis of cytotoxicity
Specific cytotoxicity of CTL lines and clones was tested by measuring specific lysis of target cells in an europium (Eu) or 51 chromium ( 51 Cr) release assay as previously described. 20, 21 Leukemic cells, patient-or donor-derived PHA-stimulated T cells (PHA blasts) and EBV-LCL, or the cell line K562 were used as target cells. Patient-derived PHA blasts and EBV-LCL did not contain the t(9;22) translocation, as determined by bcr/abl specific reversed transcriptase PCR of cDNA derived from these cells (data not shown). Specific lysis by CTL lines and clones was analyzed in a semi-quantitative way by scoring wells as positive if the number of counts in a tested well exceeded the mean +3 times the standard deviation (s.d.) of the 24 control wells, containing stimulator and target cells only. Assuming single hit kinetics and using the zero term of the Poisson equation, which predicts that when 37% of the tested wells are negative there is an average of one precursor cell per well, the CTLp frequency can be calculated. 22 A statistical program was used to calculate these frequencies. 23 Cytotoxicity was scored in a quantitative way by calculating the percentage specific lysis using the spontaneous and maximum release of 51 Cr or Eu in 4 h from at least six wells with 5 x 10 3 target cells. Spontaneous release was measured by addition of 0.1 ml medium and maximum release by 0.1 ml 1% Triton X-100 to 5 x 10 3 target cells. The percentage specific lysis of a well was calculated using 100% x (experimental release − spontaneous release)/(maximum release − spontaneous release).
As shown previously the Eu-and 51
Cr labeling methods correlated highly when PHA blasts were used as target cells. 20 Labeling of leukemic cells and EBV-LCL with 51 Cr and Eu also showed a good correlation (data not shown). For logistic reasons we therefore used the Eu release assay to analyze the reactivity of large numbers of wells and the 51 Cr release assay when the number of CTL lines or clones to be tested was limited, the target cells were available in small numbers or when blocking experiments were performed.
To determine MHC restricted lysis of targets by CTL lines and clones, blocking experiments were performed. Effector cells were incubated for 30 min with saturating concentrations of anti-CD4 (RIV6) or anti-CD8 (FK18) monoclonal antibodies or target cells were incubated with anti-HLA class II (7.5.10.1) or anti-HLA class I monoclonal antibodies (W6/32) before the effector or target cells were co-cultured.
Statistical analysis
The 2 value was used to test the correlation between cytotoxicity in the wells at different time-points. In this analysis cytotoxicity was defined as у20% lysis of the target cells. The Pearson correlation coefficient (r) was used to determine a relationship between the percentage specific lysis of patient-derived leukemic cells at different time-points.
Flow cytometric analysis
Phenotype analysis of the CTL lines and clones was performed by direct two-color flow cytometry using a FACScan (Becton Dickinson, San Jose, CA, USA) and the commercially available monoclonal antibodies against CD2, CD3, CD4, CD8, CD56 and TCR-␥␦ (Becton Dickinson, Mountain View, CA, USA). NK cells were defined as
+ cells. LDS staining was used to test the viability of analyzed cells.
Results
Generation of CTL lines in bulk cultures
CTL lines were generated in bulk cultures from the HLAidentical donors HS and IU of patients KG and EU, respectively, by stimulating donor lymphocytes with irradiated recipient-derived leukemic cells. Eleven separate IU␣EU CTL lines and six HS␣KG CTL lines were generated in bulk culture on different occasions. Proliferation and cytotoxicity of each cell line were tested after 2, 3, 4 and 5 weeks of culture. As shown in Figure 1 the proliferation of these CTL lines as measured by the fold increase in the number of cells after 4 weeks of culture showed major variations despite fixed culture conditions. The HS␣KG CTL lines showed an increase in cell number of 4-to 55-fold. Two CTL lines were negative (Ͻ10% specific lysis), one was weakly positive (10-20% lysis) and three CTL lines exhibited Ͼ20% lysis of leukemic cells when tested at an E/T ratio of 20:1 at day 28. Five of 11 consecutive attempts to generate IU␣EU CTL lines resulted in Ͼ20% specific lysis of leukemic cells, and two proliferating CTL lines showed 12-15% lysis of leukemic cells. Four attempts did not result in substantial proliferation or cytotoxicity. All CTL lines with Ͻ20% specific lysis at day 28 were also non-cytotoxic after 5 weeks of culture. These data show that specific cytotoxicity is absent in non-proliferating CTL lines. No correlation was found between the proliferation rate of the CTL lines and the magnitude of specific cytotoxicity.
The percentage specific lysis of donor-and patient- 
Generation of CTL lines in LDA
Limiting dilutions of peripheral blood MNC from the three HLA-identical donors (HS, IU and KH) were stimulated with 2 x 10 4 /well irradiated patient-derived leukemic cells (KG, EU and WH respectively). In bulk cultures IL-2 concentrations of 300 IU/ml were used, whereas in assays to determine combined HTLp and CTLp frequencies IL-2 concentrations of 120 IU/ml have been routinely used. 20 In a pilot study we tested the influence of different IL-2 concentrations on the percentage leukemia-reactive wells after 2, 3, 4 and 5 weeks of culture. No differences were found in the percentage leukemia-reactive wells and the magnitude of the response (data not shown). The relation between the initial number of responder cells per well and the percentage of leukemia-reactive wells per combination after 2, 3, 4 or 5 weeks of culture is shown in Table 1 . Table 2 shows the results of the quantitative analysis of cytotoxicity, in which wells with Ͼ20% specific lysis of leukemic cells were scored as positive. The calculated frequency of lymphocytes that gave Ͼ20% specific lysis after + and CD8 + T cell clones generated from these CTL lines by secondary limiting dilution. frequency after 2, 3 or 4 weeks of culture was stable in combination HS␣KG and therefore in this combination it could be analyzed for a correlation between the cytotoxicity in each individual well during culture. Of all leukemiareactive wells at day 21, 37% or 31% were also positive at day 14 using the semi-quantitative or quantitative analysis, respectively. As shown in Figure 3a , 66% of the wells with Ͼ20% specific lysis of leukemic cells at day 21, also gave Ͼ20% lysis at day 28. Furthermore, there was a significant correlation between cytotoxicity after 4 and 5 weeks of culture (P Ͻ 0.01). All wells from the HS␣KG LDA that showed Ͼ20% cytotoxicity against leukemic cells were phenotyped. No predominant T cell subset, defined as Ͼ50% of the viable cells, was present after 3, 4, or 5 weeks of culture. 
Expansion of CTL lines from LDA
From one LDA, 21 IU␣EU CTL lines with Ͼ20% specific lysis of the leukemic cells at day 28 were restimulated with twice as many irradiated leukemic cells at days 28 and 42 of culture. At day 49, the number of cultured cells per CTL line varied between 10 6 and 20 x 10 6 . No correlation was found between the number of viable cells and the distribution of T cell subsets (data not shown). At day 49, the cytotoxicity of these CTL lines was tested against leukemic cells, patient-or donor-derived PHA blasts and EBV-LCL, and the cell line K562 at an E:T ratio of 20:1. Four CTL lines (IU␣EU 101, 117, 118 and 121) gave stable lysis of Ͼ20% of the leukemic cells. One other CTL line (IU␣EU 108) gave Ͼ20% lysis of patient EBV-LCL with only low lysis of the malignant cells. These results show that longterm cultures of CTL lines may result in stable anti-leukemic cytotoxicity, but most CTL lines lost their specific cytotoxicity during prolonged culture. The percentage specific lysis of patient-derived leukemic cells, PHA blasts, and EBV-LCL, and cell line K562 by cell line IU␣EU 101, 108 and 121 is shown in Figure 4 . CTL line IU␣EU 117 and IU␣EU 118 gave a specific allo-reactivity pattern comparable to IU␣EU 121 and IU␣EU 101, respectively. All CTL lines were negative when tested against autologous (donor) PHA blasts or EBV-LCL.
Blocking studies were performed to analyze MHC restriction of the recognition with patient EBV-LCL as target cells in an E:T ratio of 10:1. As shown in Figure 5 cytotoxicity of CTL line 101, consisting of 83% ␥␦ T cells, could not be blocked by the antibodies tested. The activity of CTL line 108 with 80% CD4
+ cells was partially blocked by anti-CD4 or anti-class II MoAb. Anti-CD 8 and anti-class I MoAb blocked the specific lysis of patient EBV-LCL by CTL line 121 containing 66% CD8
+ cells. These results show that stable CTL lines with different phenotypes, reactive with the leukemic cells, can be generated within a single LDA. that gave 35-81% lysis of recipient leukemic cells are given in Table 3 . Only nine growing clones were harvested from the LDA of CTL line HS␣KG 2, whereas a random selection of 20 proliferating clones were harvested from the other three cell lines. Forty clones were CD8 + , 18 clones CD4 + and 11 potential clones appeared to be non-clonal. As shown in Table 3 
Generation of CTL clones
Discussion
The high response rate of donor leukocytes transfusions (DLT) in patients with a hematologic relapse of CML after SCT shows the strong anti-leukemic effect of allogeneic lymphocytes and proves the existence of a GVL effect. [6] [7] [8] [9] [10] DLT are often accompanied by GVHD, suggesting that the GVL effect is in part an alloreactive T cell response directed against (polymorphic) antigens expressed on multiple tissues from the patient. GVHD, bone marrow aplasia and infections after DLT cause a mortality of 20%. A reduction of the number of donor leukocytes infused may lower the incidence of GVHD. 11 However, the high morbidity and mortality of DLT provokes the question if in vitro selection and expansion of T cells with a relative specificity for leukemic cells may separate anti-leukemic responses from GVHD. In vitro selection, expansion and infusion of donor-derived EBV-specific T cell lines 24, 25 and anti-CMV T cell clones 26 after SCT is feasible and not correlated with GVHD. CTL responses with a relative specificity for leukemic blasts can be generated between HLAidentical individuals. [12] [13] [14] However, as shown in this study, consecutive attempts to generate anti-leukemic responses between HLA-identical individuals in bulk cultures resulted in major variations in proliferation, distribution of T cell subsets and specific lysis of leukemic cells. Several studies have also indicated that such CTL lines may lose their specificity. [16] [17] [18] Limiting dilution analysis (LDA) provides a method for the calculation of the frequency of functionally defined T lymphocytes in vitro. The allo-reactive CTLp frequency may be used to select the most optimal donor-patient pairs for an allogeneic stem cell transplantation. A significant correlation between high CTLp frequency and the severity of acute GVHD has been found. 19, 27, 28 However, some patients with high frequencies developed minimal acute GVHD, whereas other patients with low frequencies had moderate to severe GVHD. 29 A possible explanation for these differences may be the restricted tissue distribution of some minor histocompatibility (mH) antigens. 30 Antigens capable of initiating acute GVHD in a particular organ may not be expressed by the antigen-presenting cells used as stimulator cells in the LDA and hence will not be detected by the assay. On the other hand, antigens present solely on the hematopoietic stimulator cells may result in specific responses, leading to a graft-versus-hematopoietic cell or graft-versus-leukemia response rather than GVHD reaction. 13, 16, 31 A LDA can also be used to select specific CTL responses in individual wells. We used a modification of the LDA to generate leukemia-reactive CTLs by stimulating peripheral blood MNC from healthy HLA-identical stem cell donors with irradiated patient-derived CML cells. By application of split well analysis, CTL activity in each individual well could be tested with one part of the responder cells whereas the residual cells were used for further expansion. The combination of selection by testing cytotoxicity and expansion of the leukemia-reactive wells may facilitate the isolation of CTL lines with a relative specificity for the leukemic cells. Anti-leukemia reactivity in wells was found after 2-4 weeks of culture in three HLA-identical donor-recipient pairs tested. Similar to bulk cultures, differences in proliferation and anti-leukemic T cell reactivity were identified in different wells of the LDA. Multiple different types of HLA non-restricted as well as HLA-restricted anti-leukemic T cell responses can be identified and the kinetics of these responses can be studied using this modification of a LDA. The absence of stable responses in time may be explained by overgrowth or selection of non-cytotoxic T cells. However, combining the primary LDA and sequential analysis of anti-leukemic reactivity may result in CTL responses with stable proliferation and cytotoxicity, as shown by the strong correlation between the leukemia-reactive wells from combination HS␣KG after 3, 4 and 5 weeks of culture. All leukemia-reactive HS␣KG CTL lines also gave significant lysis of patient EBV-LCL. Because the EBV-LCL were bcr-abl negative, these CTL lines did not recognize a bcr-abl translocation-specific peptide. Therefore the anti-leukemic responses most probably were directed against a polymorphic antigen, present on the EBV-LCL and leukemic cells, but not on PHA blasts indicating a restricted distribution of the target antigens within the recipient. Cloning of stable donor-anti-host and also hostanti-donor CTL responses showed that multiple different T cell clones can be identified within HLA-identical combinations. 14, 32, 33 The modification of the LDA as a method for generating anti-leukemic immune responses in vitro between HLAidentical individuals has an advantage over bulk cultures by the possibility of selecting relevant stable immune responses by a limited number of lymphocytes that can respond to specific antigens present on the leukemic cells. In addition, the modification of the LDA can also be used to select the moment of the maximal anti-leukemic responsiveness between an HLA-identical donor and patient. Leukemia-reactive wells can be selected and harvested during this period of T cell expansion to be used for clinical application. At present, we have initiated a clinical protocol using the LDA as a method to select donor T cells with anti-leukemic reactivity for adoptive transfer in patients with a relapse of leukemia after SCT.
